Mr. Dan Ross, Chief Business Officer of the company, has more than 20 years of industry and strategic consulting experience in the biopharmaceutical field. He cooperated with RemeGen Since 2017, and he was tasked with promoting the company’s global partnerships. RemeGen eventually established a partnership with Seagen for the development and commercialization of Disitamab Vedotin (RC48) for 2.6 billion US dollars. Shortly thereafter, he joined RemeGen and was responsible for all internal and external strategic cooperation work. He received his MBA from the Stanford Graduate School of Business.